Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel [0.03%]
DPYD、UGT、CDA和ABCB1多态性在胰腺导管腺癌患者接受mFOLFIRINOX或吉西他滨+白蛋白结合型紫杉醇治疗中的药理基因组学分析
Caterina Vivaldi,Stefania Crucitta,Silvia Catanese et al.
Caterina Vivaldi et al.
Modified FOLFIRINOX (mFOLFIRINOX) and gemcitabine + nab-paclitaxel (GemNab) regimens represent a standard treatment in advanced pancreatic cancer (aPC). DPYD and UGT1A1 variants are relevant predictors of fluoropyrimidine and irinotecan-ass...
Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore [0.03%]
新加坡急性冠脉综合征患者基于CYP2C19指导的抗血小板治疗的成本效益分析
Ji Heon Kim,Doreen Su-Yin Tan,Mark Yan Yee Chan
Ji Heon Kim
We evaluated the cost-effectiveness of a genotype-guided strategy among patients with acute coronary syndromes using a decision-tree model based on the Singapore healthcare payer's perspective over a 1-year time horizon. Three dual antiplat...
Does the RAAS play a role in loss of taste and smell during COVID-19 infections? [0.03%]
肾素血管紧张素系统在新冠病毒感染导致的嗅觉味觉丧失中扮演角色吗？
Heloise R Luchiari,Ricardo J Giordano,Richard L Sidman et al.
Heloise R Luchiari et al.
Rapid response to the alpha-1 adrenergic agent phenylephrine in the perioperative period is impacted by genomics and ancestry [0.03%]
围术期α-1肾上腺素能药物苯肾上腺素的快速反应受到基因组学和祖先的影响
Stephane Wenric,Janina M Jeff,Thomas Joseph et al.
Stephane Wenric et al.
The emergence of genomic data in biobanks and health systems offers new ways to derive medically important phenotypes, including acute phenotypes occurring during inpatient clinical care. Here we study the genetic underpinnings of the rapid...
Implications of venous thromboembolism GWAS reported genetic makeup in the clinical outcome of ovarian cancer patients [0.03%]
遗传多态性与卵巢癌患者静脉血栓栓塞风险及临床结局的相关性研究
Valéria Tavares,Ricardo Pinto,Joana Assis et al.
Valéria Tavares et al.
Ovarian cancer (OC) represents the most lethal gynaecological neoplasia. Conversely, venous thromboembolism (VTE) and OC are intricately connected, with many haemostatic components favouring OC progression. In light of this bilateral relati...
Christopher W Meaden,Alexander Mozeika,Rijul Asri et al.
Christopher W Meaden et al.
Buprenorphine is an effective treatment for opioid dependence; however, it demonstrates individual variability in efficacy. Pharmacogenomics may explain this drug response variability and could allow for tailored therapy on an individual ba...
Population impact of pharmacogenetic tests in admixed populations across the Americas [0.03%]
药理基因组检测在美洲混血人群中的人口影响
Guilherme Suarez-Kurtz
Guilherme Suarez-Kurtz
The current population of the Americas (~1 billion people) is highly heterogeneous as a result of five centuries of admixture between three major parental populations, namely Native Amerindians, Europeans, and subSaharan Africans. This hete...
Associations between the 1438A/G, 102T/C, and rs7997012G/A polymorphisms of HTR2A and the safety and efficacy of antidepressants in depression: a meta-analysis [0.03%]
HTR2A基因的1438A/G，102T/C和rs7997012G/A多态性与抗抑郁药在抑郁症治疗中的安全性和有效性之间的关联：一项荟萃分析
Yuan-Sheng Wan,Xue-Jia Zhai,Hong-Ai Tan et al.
Yuan-Sheng Wan et al.
The correlations between hydroxytryptamine receptor 2A (HTR2A) gene polymorphisms (1438A/G, 102T/C, and rs7997012G/A) and the safety and efficacy of antidepressants in depression patients were constantly reported, but conclusions are debata...
Global distribution of CYP2C19 risk phenotypes affecting safety and effectiveness of medications [0.03%]
影响药物安全性和有效性的CYP2C19风险表型的全球分布
Mohitosh Biswas
Mohitosh Biswas
Genetic variability of CYP2C19 may affect safety or efficacy of many clinically important medications as outlined in the clinical pharmacogenetics implementation consortium (CPIC) dosing guidelines. To determine the predictive prevalence of...
Pharmacogenetic information in Swiss drug labels - a systematic analysis [0.03%]
瑞士药品标签中的药理遗传信息-系统分析
C Jeiziner,K Suter,U Wernli et al.
C Jeiziner et al.
Implementation of pharmacogenetics (PGx) and individualization of drug therapy is supposed to obviate adverse drug reactions or therapy failure. Health care professionals (HCPs) use drug labels (DLs) as reliable information about drugs. We ...